# HPW Skill - Medical Nomenclature Guidelines (v2.0)

## 1. Gene and Chromosome Nomenclature

### 1.1 HGVS-Recommended Nomenclature (2024)

**Gene Names:**
- Use *italics* for gene symbols (e.g., *BCR::ABL1*, *FLT3*, *NPM1*)
- Use upright/roman text for protein products (e.g., BCR::ABL1 protein)
- Gene symbols should be in ALL CAPS for autosomal genes (e.g., *DNMT3A*)
- Use mixed case for X-linked genes (e.g., *GATA1*, *XIST*)

**IMPORTANT - Fusion Genes (HGVS 2024 / ISCN 2024):**
- Use **DOUBLE COLON (::)** for fusion genes (NEW in 2024)
- *BCR::ABL1* (NOT BCR-ABL1 or BCR/ABL)
- *PML::RARA* (NOT PML-RARA or PML/RARA)
- *RUNX1::RUNX1T1* (NOT RUNX1-RUNX1T1)
- *CBFB::MYH11*, *DEK::NUP214*, *MLLT3::KMT2A*, *ETV6::RUNX1*

**Variant Nomenclature:**
- Use HGVS nomenclature for all sequence variants
- Prefix with "c." for coding DNA variants (e.g., c.1794T>G)
- Use "p." prefix for protein changes (e.g., p.Val617Phe)
- Use "g." for genomic coordinates (e.g., g.12345678G>A)
- Fusion genes use :: notation (see above)

**Correct Examples:**
- *BCR::ABL1* fusion gene (NEW format!)
- *NPM1* mutation (NPM1 WT = wild-type)
- *FLT3*-internal tandem duplication (FLT3-ITD)
- *TP53* loss-of-function variant
- Complex karyotype with del(5q), -7, and i(17q)

**Incorrect Examples:**
- BCR-ABL fusion (use *BCR::ABL1*)
- NPM1 mutation (not italicized)
- FLT3 internal tandem duplication (not hyphenated)
- p53 (should be *TP53* for gene)

### 1.2 Cytogenetic Nomenclature (ISCN 2024)

**Structural Abnormalities:**
- del = deletion (e.g., del(5q))
- inv = inversion (e.g., inv(16)(p13.1q22))
- t = translocation (e.g., t(9;22)(q34;q11))
- ins = insertion
- add = additional material of unknown origin
- i = isochromosome (e.g., i(17q))
- der = derivative chromosome

**Numerical Abnormalities:**
- - = monosomy (e.g., -7)
- + = trisomy (e.g., +8)
- cp = complex karyotype (≥3 abnormalities)

**Fusion Genes from Translocations (HGVS 2024):**
- t(9;22)(q34;q11) → *BCR::ABL1*
- t(8;21)(q22;q22) → *RUNX1::RUNX1T1*
- t(15;17)(q22;q12) → *PML::RARA*
- inv(16)(p13.1q22) → *CBFB::MYH11*

---

## 2. WHO vs ICC Classification

### 2.1 WHO Classification 2022 (5th Edition)

**Key Features:**
- Myeloid neoplasms and acute leukemias
- Integrated approach: morphology, immunophenotype, genetics
- Defined genetic entities as primary classification criterion

**AML Classification:**
- AML with defining genetic abnormalities
- AML with myelodysplasia-related changes
- Therapy-related AML
- AML not otherwise specified

**Key Genetic Entities:**
- AML with t(8;21)(q22;q22); *RUNX1::RUNX1T1*
- AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB::MYH11*
- APL with t(15;17)(q22;q12); *PML::RARA*
- AML with t(9;11)(p21.3;q23.3); *MLLT3::KMT2A*
- AML with *NPM1* mutation
- AML with *CEBPA* bZIP mutation

### 2.2 ICC Classification 2022 (International Consensus Classification)

**Key Features:**
- Separates myeloid and lymphoid neoplasms
- More explicit genetic criteria
- New entities and refined categories

**Differences from WHO:**
1. **Terminology:** "myeloid neoplasms" vs "myeloproliferative neoplasms"
2. **MDS Classification:** Different risk stratification
3. **AML Definition:** Lower blast threshold for some entities
4. **New Entities:** More genetically-defined categories

**Side-by-Side Comparison:**

| Feature | WHO 2022 | ICC 2022 |
|---------|----------|----------|
| AML blast threshold | ≥20% | ≥20% (or specific genetic abnormality) |
| MDS-EB | 2 subcategories | 2 subcategories (different thresholds) |
| *NPM1*-mutated AML | Separate entity | Separate entity |
| *TP53*-mutated AML | Separate entity | Separate entity with MDS/AML |
| APL | PML-RARA required | PML-RARA required |

**IMPORTANT - Fusion Gene Notation in Classification:**
Both WHO 2022 and ICC 2022 now reference fusion genes using HGVS 2024 notation:
- WHO 2022: AML with *RUNX1::RUNX1T1* (not RUNX1-RUNX1T1)
- ICC 2022: AML with *PML::RARA* (not PML-RARA)

---

## 3. ELN Recommendations

### 3.1 ELN 2022 AML Recommendations

**Risk Stratification (by genetics):**

**Favorable Risk:**
- t(8;21)(q22;q22); *RUNX1::RUNX1T1*
- inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB::MYH11*
- *NPM1* mutation without *FLT3*-ITD or with *FLT3*-ITD low allelic ratio
- *CEBPA* bZIP mutation (double allele)

**Intermediate Risk:**
- *NPM1* mutation with *FLT3*-ITD high allelic ratio
- Wild-type *NPM1* without *FLT3*-ITD or with *FLT3*-ITD low allelic ratio
- t(9;11)(p21.3;q23.3); *MLLT3::KMT2A*
- Other cytogenetic abnormalities not classified

**Adverse Risk:**
- t(6;9)(p23;q34.1); *DEK::NUP214*
- t(v;11q23.3); *KMT2A* rearranged
- t(9;22)(q34;q11); *BCR::ABL1*
- Complex karyotype (≥3 abnormalities)
- Monosomy 5/del(5q)
- *TP53* mutation/abnormality

### 3.2 ELN 2025 CML Recommendations

**Response Definitions:**

**Optimal Response:**
- *BCR::ABL1* ≤10% at 3 months
- *BCR::ABL1* ≤1% at 6 months
- *BCR::ABL1* ≤0.1% (MR2) at 12 months
- *BCR::ABL1* ≤0.01% (MR3) by 18 months

**Warning:**
- *BCR::ABL1* >10% at 3 months
- *BCR::ABL1* >1% at 6 months
- *BCR::ABL1* >0.1% at 12 months

**Failure:**
- *BCR::ABL1* >10% at 6 months
- *BCR::ABL1* >1% at 12 months
- Loss of CHR, CCyR, or MMR
- *BCR::ABL1* kinase domain mutation

---

## 4. NIH GVHD Diagnosis and Grading

### 4.1 Acute GVHD Staging

**Skin:**
- Stage 1: Maculopapular rash <25% BSA
- Stage 2: Maculopapular rash 25-50% BSA
- Stage 3: Maculopapular rash >50% BSA
- Stage 4: Generalized erythroderma + bullae

**Liver (Bilirubin):**
- Stage 1: 2-3 mg/dL
- Stage 2: 3-6 mg/dL
- Stage 3: 6-15 mg/dL
- Stage 4: >15 mg/dL

**Gut:**
- Stage 1: 500 mL diarrhea/day
- Stage 2: 500-1000 mL/day
- Stage 3: >1000 mL/day
- Stage 4: Grade 3 + severe abdominal pain

### 4.2 Chronic GVHD Severity

**Mild (1):**
- 1-2 organs involved
- No significant functional impairment

**Moderate (2):**
- 1-3 organs involved
- Mild-moderate functional impact

**Severe (3):**
- 3+ organs involved
- Significant functional impairment

---

## 5. Reference Standards

### 5.1 Primary References

1. **WHO Classification 2022:** Blood. 2022;140(11):1345-1374. doi:10.1182/blood.2022015850
2. **ICC Classification 2022:** Blood Adv. 2022;6(18):5128-5148. doi:10.1182/bloodadvances.2022016867
3. **ELN AML 2022:** Leukemia. 2022;36(7):1703-1719. doi:10.1038/s41375-022-01613-1
4. **ELN CML 2025:** Leukemia. 2025;39(3):xxx-xxx. doi:10.1038/s41375-025-02664-w
5. **HGVS Nomenclature 2024:** https://hgvs-nomenclature.org
6. **ISCN 2024:** https://iscn.cog-repository.org
7. **NIH GVHD Consensus:** Biol Blood Marrow Transplant. 2005;11(12):945-956

---

## 6. Quick Reference: Fusion Genes (HGVS 2024 / ISCN 2024)

### THE NEW STANDARD: DOUBLE COLON (::)

| Fusion Gene | CORRECT (2024) | OLD (Deprecated) |
|-------------|----------------|-----------------|
| Philadelphia | *BCR::ABL1* | BCR-ABL1, BCR/ABL |
| APL | *PML::RARA* | PML-RARA, PML/RARA |
| AML with t(8;21) | *RUNX1::RUNX1T1* | RUNX1-RUNX1T1 |
| AML with inv(16) | *CBFB::MYH11* | CBFB-MYH11 |
| AML with t(6;9) | *DEK::NUP214* | DEK-NUP214 |
| AML with t(9;11) | *MLLT3::KMT2A* | MLLT3-KMT2A |
| B-ALL with t(12;21) | *ETV6::RUNX1* | ETV6-RUNX1 |

### Manuscript Example (CORRECT)

> Cytogenetic analysis revealed the Philadelphia chromosome with the *BCR::ABL1* fusion gene in 95% of metaphases. RT-PCR confirmed the e1a2 transcript. The patient achieved complete cytogenetic response at 6 months with *BCR::ABL1* transcript levels of 0.8% IS.

---

## 7. HPW Implementation Guidelines

### 7.1 Template Usage

When generating manuscripts, apply nomenclature rules based on:
1. **Genetics section:** HGVS 2024 + ISCN 2024 nomenclature
2. **Diagnosis section:** WHO vs ICC comparison
3. **AML/CML context:** ELN recommendations
4. **Transplant context:** NIH GVHD criteria

### 7.2 Quality Checks

- [ ] Fusion genes use double colon (*BCR::ABL1*, not BCR-ABL1)
- [ ] Gene symbols italicized
- [ ] HGVS variant nomenclature correct
- [ ] ISCN cytogenetic notation correct
- [ ] Risk stratification uses ELN criteria
- [ ] GVHD staging uses NIH criteria

### 7.3 Example Text (CORRECT)

"Patient presented with AML with *NPM1* mutation and *FLT3*-ITD (allelic ratio 0.45). Cytogenetic analysis revealed a complex karyotype: 46,XX,del(5q),-7,i(17q)[12]/46,XX[8]. According to ELN 2022 criteria, this patient was classified as adverse risk due to the *BCR::ABL1*-negative but complex karyotype with -5/del(5q) and -7."

### 7.4 Example Text (INCORRECT)

"Patient had AML with NPM1 mutation and FLT3 ITD. Cytogenetics showed 5q deletion, monosomy 7, and 17q isochromosome. This was adverse risk per ELN 2022. The BCR-ABL1 fusion was negative."

---

## 8. HGVS 2024 Key Updates

### 8.1 Major Changes

1. **Fusion Genes:** Now use double colon (::) notation
2. **Somatic Variants:** Separate notation with VAF when available
3. **CNVs:** Updated standards for duplications/deletions
4. **Reference Sequences:** More specific requirements

### 8.2 Citation

Hart RK, Fokkema IFAC, DiStefano M, et al. HGVS Nomenclature 2024: Improvements to community engagement, usability, and computability. Genome Med. 2024;16:149. doi:10.1186/s13073-024-01421-5
